INT113263

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 13
Disease Relevance 1.19
Pain Relevance 1.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
cartridge 4
neutrophil 1
TSPAN33 (Homo sapiens)
Pain Link Frequency Relevance Heat
Enkephalin 4 100.00 Very High Very High Very High
Dynorphin 1 100.00 Very High Very High Very High
Morphine 1 96.84 Very High Very High Very High
Opioid 9 94.72 High High
Pain 20 90.52 High High
antagonist 1 75.08 Quite High
Endogenous opioid 1 40.24 Quite Low
Kappa opioid receptor 1 35.52 Quite Low
Inflammation 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adhesions 5 96.36 Very High Very High Very High
Confusion 11 94.76 High High
Cancer 6 92.32 High High
Skin Cancer 1 85.44 High High
INFLAMMATION 2 78.96 Quite High
Obesity 9 74.36 Quite High
Diabetes Mellitus 9 65.32 Quite High
Ovarian Hyperstimulation Syndrome 36 33.40 Quite Low
Spontaneous Abortion 9 18.96 Low Low
Rheumatoid Arthritis 12 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: The endogenous opioid peptides beta-endorphin(1-31) and met-enkephalin, representing the N-terminal fragment of beta-endorphin(1-31), and the synthetic delta opioid receptor agonists D-Ala(2)-D-Leu(5)-enkephalin and D-Pen(2)-enkephalin produced concentration-dependent stimulation of neutrophil activity.
Gene_expression (produced) of Pen in neutrophil
1) Confidence 0.65 Published 2003 Journal Br J Anaesth Section Body Doc Link 14504158 Disease Relevance 0.08 Pain Relevance 0
OGF and NTX at concentrations of 10(-4) to 10(-6)M, and dynorphin A1-8, beta-endorphin, endomorphin-1, endomorphin-2, leucine enkephalin, [D-Pen(2,5)]-enkephalin (DPDPE), [D-Ala(2), MePhe(4), Glycol(5)]-enkephalin (DAMGO), morphine, and U69,593 at concentrations of 10(-6)M, did not alter cell migration, chemotaxis, or invasion of any cancer cell line.
Gene_expression (concentrations) of Pen associated with dynorphin, cancer, enkephalin and morphine
2) Confidence 0.65 Published 2007 Journal Neuropeptides Section Abstract Doc Link 17910895 Disease Relevance 0.88 Pain Relevance 1.01
Finally, we evaluated the Ubi-Pen
Gene_expression (evaluated) of Ubi-Pen
3) Confidence 0.41 Published 2008 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2246069 Disease Relevance 0 Pain Relevance 0
In a previous version of the Ubi-Pen, there is a short-term
Gene_expression (version) of Ubi-Pen
4) Confidence 0.41 Published 2008 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2246069 Disease Relevance 0 Pain Relevance 0
Patients who had used the prefilled follitropin alfa pen (1040 respondents) and follitropin beta pen (50 respondents) reported that they changed the pen/cartridge a mean value of 2.3 and 2.4 times per treatment cycle, respectively.
Gene_expression (used) of pen in cartridge
5) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0 Pain Relevance 0
Routine daily use of the prefilled follitropin alfa pen
Gene_expression (prefilled) of pen
6) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0 Pain Relevance 0
Patients who had used the prefilled follitropin alfa pen (1040 respondents) and follitropin beta pen (50 respondents) reported that they changed the pen/cartridge a mean value of 2.3 and 2.4 times per treatment cycle, respectively.
Gene_expression (prefilled) of pen in cartridge
7) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0 Pain Relevance 0
Patients who had used the prefilled follitropin alfa pen (1040 respondents) and follitropin beta pen (50 respondents) reported that they changed the pen/cartridge a mean value of 2.3 and 2.4 times per treatment cycle, respectively.
Gene_expression (used) of pen in cartridge
8) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0 Pain Relevance 0
Results from comparative studies of the two available pen devices for injection of r-hFSH indicate a preference for the prefilled follitropin alfa pen among both patients and nurses [15,16].
Gene_expression (prefilled) of pen
9) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0.07 Pain Relevance 0.16
Initial use of the prefilled follitropin alfa pen
Gene_expression (prefilled) of pen
10) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0.07 Pain Relevance 0
In the same study, nurses were asked to complete a questionnaire about their experiences with the prefilled follitropin alfa pen and they were also very positive about the pen [15].
Gene_expression (experiences) of pen
11) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0.09 Pain Relevance 0
Patients who had used the prefilled follitropin alfa pen (1040 respondents) and follitropin beta pen (50 respondents) reported that they changed the pen/cartridge a mean value of 2.3 and 2.4 times per treatment cycle, respectively.
Gene_expression (prefilled) of pen in cartridge
12) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0 Pain Relevance 0
A greater proportion of patients in the group using the prefilled follitropin alfa pen found the pen very easy to handle, and quicker to learn to use and prepare for injection than those using the reusable follitropin beta pen.
Gene_expression (using) of pen
13) Confidence 0.28 Published 2010 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2949697 Disease Relevance 0 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox